KR101002791B1 - Ｈｃｖ ｅ2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 ｆａｂ 단편 - Google Patents

Ｈｃｖ ｅ2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 ｆａｂ 단편 Download PDF

Info

Publication number
KR101002791B1
KR101002791B1 KR1020047011208A KR20047011208A KR101002791B1 KR 101002791 B1 KR101002791 B1 KR 101002791B1 KR 1020047011208 A KR1020047011208 A KR 1020047011208A KR 20047011208 A KR20047011208 A KR 20047011208A KR 101002791 B1 KR101002791 B1 KR 101002791B1
Authority
KR
South Korea
Prior art keywords
ser
thr
gly
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047011208A
Other languages
English (en)
Korean (ko)
Other versions
KR20040077745A (ko
Inventor
로베르토 부리오니
Original Assignee
제너럴 앤티바디스 앤드 바이오테크날러지스 에스.알.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제너럴 앤티바디스 앤드 바이오테크날러지스 에스.알.엘. filed Critical 제너럴 앤티바디스 앤드 바이오테크날러지스 에스.알.엘.
Publication of KR20040077745A publication Critical patent/KR20040077745A/ko
Application granted granted Critical
Publication of KR101002791B1 publication Critical patent/KR101002791B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020047011208A 2002-01-30 2003-01-29 Ｈｃｖ ｅ2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 ｆａｂ 단편 Expired - Fee Related KR101002791B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
ITRM2002A000049 2002-01-30
PCT/IT2003/000032 WO2003064473A2 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity

Publications (2)

Publication Number Publication Date
KR20040077745A KR20040077745A (ko) 2004-09-06
KR101002791B1 true KR101002791B1 (ko) 2010-12-21

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047011208A Expired - Fee Related KR101002791B1 (ko) 2002-01-30 2003-01-29 Ｈｃｖ ｅ2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 ｆａｂ 단편

Country Status (17)

Country Link
US (2) US20050084845A1 (enExample)
EP (1) EP1476468B9 (enExample)
JP (1) JP4287280B2 (enExample)
KR (1) KR101002791B1 (enExample)
CN (1) CN1856508A (enExample)
AT (1) ATE407147T1 (enExample)
AU (1) AU2003208000B2 (enExample)
CA (1) CA2474801C (enExample)
DE (1) DE60323333D1 (enExample)
DK (1) DK1476468T3 (enExample)
EA (1) EA009861B1 (enExample)
ES (1) ES2314179T3 (enExample)
IT (1) ITRM20020049A1 (enExample)
NZ (1) NZ534922A (enExample)
RU (1) RU2004126238A (enExample)
WO (1) WO2003064473A2 (enExample)
ZA (1) ZA200406187B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
WO2008107187A1 (en) * 2007-03-06 2008-09-12 Ribovax Biotechnologies S.A. Antibodies specific for rubella virus
CN101809033A (zh) 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
AU2008341542B2 (en) * 2007-12-17 2014-12-04 Medical Research Council Technology Hepatitis C virus antibodies
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
JP6095984B2 (ja) 2010-03-01 2017-03-15 アニョロ, ヴィンセントAGNELLO, Vincent Ｈｃｖ感染患者のクリオグロブリン血症性血管炎およびｂ細胞悪性腫瘍のための予後マーカー
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
CN118440204A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
US20230312744A1 (en) 2020-09-02 2023-10-05 The University Of Tokyo Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same
US20250375498A1 (en) 2022-07-28 2025-12-11 The University Of Tokyo Neurotrimin function inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951646B1 (en) * 1998-07-21 2005-10-04 Genmab A/S Anti hepatitis C virus antibody and uses thereof
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001273363A1 (en) 2000-07-12 2002-01-21 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
JP2004524829A (ja) * 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of General Virology, Vol.81, pp.2451-2459(2000)*
Virology, Vol.288, pp.29-35(2001.09.15.)*

Also Published As

Publication number Publication date
KR20040077745A (ko) 2004-09-06
EP1476468B1 (en) 2008-09-03
WO2003064473A2 (en) 2003-08-07
EA200401081A1 (ru) 2005-10-27
US7727529B2 (en) 2010-06-01
JP4287280B2 (ja) 2009-07-01
JP2005531286A (ja) 2005-10-20
ITRM20020049A1 (it) 2003-07-30
CA2474801A1 (en) 2003-08-07
NZ534922A (en) 2008-07-31
EA009861B1 (ru) 2008-04-28
ES2314179T3 (es) 2009-03-16
CA2474801C (en) 2012-03-20
WO2003064473A3 (en) 2003-12-24
US20080241162A1 (en) 2008-10-02
US20050084845A1 (en) 2005-04-21
ZA200406187B (en) 2006-06-28
DE60323333D1 (de) 2008-10-16
EP1476468B9 (en) 2009-04-08
ATE407147T1 (de) 2008-09-15
AU2003208000B2 (en) 2010-05-20
CN1856508A (zh) 2006-11-01
EP1476468A2 (en) 2004-11-17
RU2004126238A (ru) 2005-04-20
ITRM20020049A0 (it) 2002-01-30
DK1476468T3 (da) 2009-01-19

Similar Documents

Publication Publication Date Title
KR101002791B1 (ko) Ｈｃｖ ｅ2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 ｆａｂ 단편
CN112250763B (zh) 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途
AU2022202819C1 (en) Antibody-mediated neutralization of Chikungunya virus
US6951646B1 (en) Anti hepatitis C virus antibody and uses thereof
AU2003208000A1 (en) Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
KR20240006575A (ko) SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
KR20230142790A (ko) 코로나바이러스 스파이크 단백질(spike protein)을 타겟팅하는 항체
KR102748987B1 (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
KR20110096591A (ko) Ｈｃｖ 감염의 치료적 처리 및 예방을 위한 의약으로서 항 ｈｃｖ 모노클로날 항체
US20230312689A1 (en) Human antibody or antigen-binding fragment thereof against coronavirus spike protein
KR20220098003A (ko) 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
KR20220054080A (ko) SARS-CoV-2 스파이크 단백질에 특이적으로 결합하는 항체 및 이의 용도
US12410239B2 (en) Anti-hepatitis B virus antibody and uses thereof
KR20230083288A (ko) 코로나바이러스 스파이크 단백질에 대한 단일클론 항체, 및 이의 용도
HK40072444A (en) Antibody-mediated neutralization of chikungunya virus
CN117836322A (zh) 针对SARS-CoV-2的人中和单克隆抗体及其用途
AU2020273365A1 (en) Human antibodies to Ross River virus and methods of use therefor
KR20220103761A (ko) 지카 바이러스를 중화하는 인간 항체 및 이의 사용 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20131205

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20141204

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20151203

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20161201

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20171201

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20181206

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20191205

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211215

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211215

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000